Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.54 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.47 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.46 |
| ▸ | KCNA6 | P17658 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TOP2A | P11388 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11612130 | 0.88 | MAP2K1 (0.55) | DAOMAP2K1KCNA2KCNA6NT5E | |
| SCHEMBL11607646 | 0.85 | MAP2K1 (0.52) | DAOMAP2K1KCNA2KCNA6NT5E | |
| SCHEMBL11605882 | 0.83 | MAP2K1 (0.50) | DAOMAP2K1KCNA2KCNA6NT5E | |
| SCHEMBL11612216 | 0.83 | MAP2K1 (0.50) | DAOMAP2K1KCNA2KCNA6NT5E | |
| SCHEMBL7144789 | 0.81 | KDM4E (0.55) | DAOMAP2K1KCNA2KCNA6NT5E | |
| SCHEMBL3425306 | 0.80 | CYP1A2 (0.46) | DAOMAP2K1KCNA2KCNA6NT5E | |
| SCHEMBL13042353 | 0.79 | DAO (0.47) | DAOMAP2K1KCNA2KCNA6NT5E | |
| SCHEMBL7152545 | 0.79 | MAP2K1 (0.48) | DAOMAP2K1KCNA2KCNA6NT5E | |
| SCHEMBL11607921 | 0.75 | MAP2K1 (0.62) | DAOMAP2K1KCNA2KCNA6NT5E | |
| SCHEMBL7848395 | 0.75 | LMNA (0.50) | LMNAL3MBTL1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713958-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-05-11 | — | — | US | disclosed |
| US-20090137555-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| US-7423031-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-09-09 | — | — | US | disclosed |
| US-20050153955-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-07-14 | — | — | US | disclosed |
| WO-2004098520-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153955-A1 | Compounds and compositions as protein kinase inhibitors | CDK1, CDK3, CDK11A | DAO 4328/4885MAP2K1 274/4885KCNA2 2538/4885 |
| US-20090137555-A1 | Compounds and Compositions as Protein Kinase Inhibitors | CDK1, CDK3, CDK2 | DAO 4161/4885MAP2K1 283/4885KCNA2 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.